Atara Biotherapeutics, Inc. · NASDAQ:ATRA
Atara Biotherapeutics — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
18 slides from Atara Biotherapeutics's conference presentation, Jan 8, 2024
Slide 1: 42nd Annual J.P. Morgan Healthcare Conference
Investor presentation 42nd Annual j.p. morgan healthcare conference monday, January 8, 2024 Nasdaq: ATRA Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prese
Slide 3: First Company to Obtain Regulatory Approval for an Allogeneic T-cell Immunotherapy
First Company to Obtain Regulatory Approval for an Allogeneic T-cell Immunotherapy EbvalloTM Approved by EMA in December 2022; BLA submission expected in Q2 2024 Expanded global tab-cel® partnership with Pierre Fabre closed in December 2023 Near-Term Milestones with ATA3219, Allogeneic CD19 CAR T Ce
Slide 4: Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories Closed in December 2023
Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories Closed in December 2023 Pierre Fabre Laboratories license for tab-cel global development, manufacturing and commercialization, with up to $640 million in potential consideration and significant double-digit tiered royalties Pierre F
Slide 5: Tab-cel BLA Submission on Track for Q2 2024 Based on Strong Clinical File
Tab-cel BLA Submission on Track for Q2 2024 Based on Strong Clinical File Latest Phase 3 ALLELE data cut analysis reinforces confidence in tab-cel BLA filing package 49% ORR (p<0.0001) in patient population aligned with intended U.S. label Favorable and consistent safety profile Other findings consi
Slide 6: The Only Allogeneic T-cell Platform With an Approved Product
Allogeneic EBV T-Cell Next-gen Allogeneic CAR T The Only Allogeneic T-cell Platform With an Approved Product Designed to target root cause of EBV-driven diseases No gene editing of the TCR Minimal HLA matching required Favorable safety profile Robust manufacturing process Retains beneficial features
Slide 7: Strategic Focus on Allogeneic CAR T Programs for Heme Malignancies and Autoimmune Conditions
Strategic Focus on Allogeneic CAR T Programs for Heme Malignancies and Various Autoimmune Conditions Develop best-in-class allogeneic programs for NHL and B-cell malignancies Establish promise of allogeneic CAR T across autoimmune diseases, starting in Lupus Nephritis ` ` Hematological Malignancies
Slide 8: Atara's Allogeneic CAR T Platform is Differentiated and has Potential to be Best-in-Class
Other Allogeneic CAR Platforms Atara’s Allogeneic CAR T Platform is Differentiated and has Potential to be Best-in-Class CAR Αβ T (gene-edited) CAR-NK CAR γδ Safety Safer than auto CAR T Some require high and prolonged lymphodepletion Expansion Moderate Minimal; high dose needed Minimal Persistence
Slide 9: Clinical Validation From Industry Leaders Substantiates Key Attributes of Our Allogeneic CAR T Platform
1. Park, JH et al. Poster 163A. ASH 2022. 2. Curran KJ, et al. ASH 2023. 3. Barba, P et al. Poster 439. ASH 2022. 9 Clinical Validation From Industry Leaders Substantiates Key Attributes of Our Allogeneic CAR T Platform TAK-940 CD19 auto CAR T with 1XX Dose level 1 (25M) resulted in ORR 89%, CR 78%
Slide 10: Our Allogeneic CAR T Cell Programs Incorporate Clinically Validated Technologies
Our Allogeneic CAR T Cell Programs Incorporates Clinically Validated Technologies Target: CD19+ B-cell malignancies, Autoimmune Target: CD19/CD20+ B-cell malignancies, Autoimmune EBV TCR Partially Matched MHC Novel 1XX costimulatory domain Novel 1XX costimulatory domain Partially Matched MHC EBV TCR
Slide 11: ATA3219 in NHL: Opportunity To Compete With a Differentiated Profile
Access challenges for auto CAR T Only ~10-20% of DLBCL patients receive autologous CD19 CAR T today, despite being eligible1,2 Durability challenges for auto CAR T Only ~30-40% of those who receive autologous CD19 CAR T therapy have durable response at 6 months3† 10-20% 30-40% ~15,000 CD19 CAR T-cel
Slide 12: ATA3219 in NHL: IND Cleared and Phase 1 Study Commencing
ATA3219 pre-clinical data demonstrated long-term in vivo expansion, polyfunctional phenotype, and efficient targeting of CD19 expressing tumor cells with low alloreactivity5 ATA3219 in NHL: IND Cleared and Phase 1 Study Commencing for Atara's First Allogeneic CAR T 1. Park, JH et al. Poster 163A. AS
Slide 13: ATA3219 in NHL: Potential Best-in-Class Profile as Pre-Clinical Data Supports Superior Persistence
ATA3219 in NHL: Potential "Best-in-Class" Profile as Pre-Clinical Data Supports Superior Persistence and Anti-Tumor Efficacy Pham, C, et al. Abstract presented at Transplantation & Cellular Therapy (TCT) Meetings; 2023 Note: T-cell infusion on day 3 day after tumor implantation (day 0); infusion tim
Slide 14: ATA3219 in Autoimmune: Rapidly Advancing in Lupus Nephritis
Timeline Planned IND in Lupus Nephritis in Q1’ 24 ATA3219 in Autoimmune: In a Field With Growing Momentum, Atara is Rapidly Advancing in Lupus Nephritis Unmet Need High unmet medical need in Lupus Nephritis; standard of care and approved products have limited efficacy Proof of Concept Compelling val
Slide 15: ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing With IND-Enabling Studies
ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing With IND-Enabling Studies Positive preclinical data presented at American Society of Hematology meeting in December 20231 Targeting CD19 and CD20 reduces probability of relapse due to CD19 antigen loss, hypothesized to be a major
Slide 16: ATA3431: Proof-of-Concept and Competitive Profile
ATA3431: Compelling Proof-of-Concept and Competitive Profile Challenging CD19low / CD20+ Raji model ATA3431 advancing into IND-enabling studies Greater Anti-Tumor Efficacy vs CD19/CD20 Autologous Benchmark Cha, S et al. Poster 4800. ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Tr
Slide 17: Differentiated Allogeneic T-Cell Immunotherapy Pipeline
Differentiated Allogeneic T-Cell Immunotherapy Pipeline Excluding EbvalloTM in EU, these investigational agents are not approved by any regulatory agencies and efficacy and safety have not been established. EBV+ PTLD: EBV-Associated Post-Transplant Lymphoproliferative Disease; RR: rituximab relapsed
Slide 18: Thank You
THANK YOU Nasdaq: ATRA ATARA BIO
Atara Biotherapeutics — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix